Skip to content
    ALT
    Earnings call· Jun 2026(Q2 FY26)

    Altimmune Q2 FY26 earnings call ALT

    Aug 12, 2026 Source

    Executive summary

    Altimmune Q2 FY26 — MASH Phase 3 Initiated, Strong AUD Phase 2 Data

    Altimmune is rapidly advancing its pemvidutide liver franchise, initiating the global PERFORMA Phase 3 trial for MASH and reporting robust Phase 2 data for Alcohol Use Disorder (AUD). The company is focused on leveraging pemvidutide's differentiated dual mechanism to address serious liver diseases, with a strong cash position supporting its MASH program through 2029. Management plans to pursue non-dilutive funding for the AUD Phase 3 trial.

    Highlights

    5
    • Initiation of the global PERFORMA Phase 3 trial in MASH, just 3 months after securing financial resources.

    • Positive top-line data from the RECLAIM Phase 2 trial in AUD, showing a statistically significant reduction of 1.45 heavy drinking days per week versus placebo.

    • RECLAIM trial met two FDA-recognized registrational secondary endpoints: roughly two-thirds of pemvi patients achieved a 2-level reduction in WHO RDL versus one-third on placebo, and more than twice the number of pemvi patients achieved 0 heavy drinking days versus placebo.

    • Pemvidutide demonstrated a 9.1% reduction in body weight from baseline versus placebo in the RECLAIM AUD trial.

    • Strong cash position of $519 million as of June 30, 2026, providing operating cash runway through the PERFORMA Phase 3 MASH 52-week data readout in 2029.

    Concerns

    3
    • R&D expense increased to $18.7 million in Q2 FY26 from $17.2 million in Q2 FY25, driven by investment into the ALD trial and MASH Phase 3 startup costs.

    • G&A expenses increased to $7.6 million in Q2 FY26 from $5.7 million in Q2 FY25, primarily due to higher professional fees and compensation expenses.

    • The potential AUD Phase 3 trial is not yet funded, with the company planning to use non-dilutive means.

    Guidance & targets

    2
    CategoryTargetConfidence
    Cash runway
    Through PERFORMA Phase 3 MASH 52-week data readout
    high materiality
    High
    AUD Phase 3 funding
    Non-dilutive means
    medium materiality
    Medium

    Operational metrics

    23
    R&D expense
    $18.7Mvs $17.2M in Q2 FY25
    Q2 FY26

    Increase in R&D spend was driven by investment into our ALD trial, as well as startup costs for the Phase 3 trial in MASH, offset by a decrease in expenses related to the completion of the Phase 2 trial in MASH, which was ongoing in 2025.

    R&D direct costs for pemvidutide development
    $11.6M
    Q2 FY26

    Q2 '26 R&D spend included $11.6 million of direct costs related to pemvidutide development, of which $3.8 million was for MASH, $5.3 million for the Phase 2 AUD and ALD trials, and $2.5 million in CMC-related expenses.

    R&D non-cash stock compensation
    $1.1M
    Q2 FY26

    Q2 '26 R&D also included $1.1 million in non-cash stock compensation.

    G&A expenses
    $7.6Mvs $5.7M in Q2 FY25
    Q2 FY26

    The increase in G&A was driven by an increase in professional fees and compensation expenses.

    G&A non-cash stock compensation
    $1.7M
    Q2 FY26

    And the Q2 '26 G&A included $1.7 million in non-cash stock comp.

    Net loss
    $22.8Mvs $22.1M in Q2 FY25
    Q2 FY26

    Net loss for the second quarter of 2026 was $22.8 million, or $0.12 a share, compared to a net loss of $22.1 million, or $0.27 a share in the second quarter of 2025.

    EPS
    $0.12vs $0.27/share in Q2 FY25
    Q2 FY26

    Net loss for the second quarter of 2026 was $22.8 million, or $0.12 a share, compared to a net loss of $22.1 million, or $0.27 a share in the second quarter of 2025.

    Total cash
    $519M
    As of June 30, 2026

    June 30, 2026 total cash was $519 million.

    Capital raised year-to-date
    $310M
    YTD 2026

    Since the beginning of the year, we strengthened our financial position, having raised approximately $310 million year-to-date, including the $225 million follow-on offering in April.

    PERFORMA Phase 3 MASH trial sites
    300
    Global

    The trial will be conducted across approximately 300 sites with one-third in the U.S. and two-thirds outside.

    PERFORMA Phase 3 MASH enrollment timeline
    lower end of 18-24 months
    Future

    Our enrollment is around, for studies in that nature, between 18 to 24 months. We are, because of this, different aspects that are, we heard they are very attractive for the PIs. We are aiming at the lower end of this, and that fits well with what we're hearing right now.

    RECLAIM Phase 2 AUD heavy drinking days reduction
    1.45vs placebo
    Week 24

    The trial met its primary endpoints where pemvidutide 2.4 mg showed a highly statistically significant reduction in the average number of heavy drinking days versus placebo at week 24 with a treatment difference of 1.45 heavy drinking days per week.

    RECLAIM Phase 2 AUD 2-level WHO RDL reduction
    two-thirdsvs one-third on placebo
    Week 24

    Roughly two-thirds of pemvi patients achieved a 2-level reduction in WHO RDL. This is only one-third on placebo.

    RECLAIM Phase 2 AUD 0 heavy drinking days
    more than twicevs placebo patients
    Week 24

    In these data, more than twice the number of the pemvi patients achieved 0 heavy drinking days versus placebo patients.

    RECLAIM Phase 2 AUD body weight reduction
    9.1%vs placebo
    From baseline

    Pemvi also showed a meaningful and statistically significant reduction in body weight from baseline with a 9.1% reduction with pemvidutide versus placebo.

    RECLAIM Phase 2 AUD FIB-4 improvement
    50%vs 17% in placebo
    24 weeks

    The observed data with 50% of pemvidutide patients with a FIB-4 index above 1.3 at baseline, achieving less than 1.3 after only 24 weeks, versus only 17% in placebo, is very encouraging, especially at such an early time point.

    US adults with moderate to severe AUD
    12M
    Current

    There are approximately 12 million adults in the U.S. with moderate to severe AUD.

    AUD patients diagnosed
    10%
    Current

    Overall, only 10% of AUD patients are diagnosed, and of those, only 1 in 4 receives drug therapy.

    Diagnosed AUD patients receiving drug therapy
    1 in 4
    Current

    Overall, only 10% of AUD patients are diagnosed, and of those, only 1 in 4 receives drug therapy.

    Hepatologists using PEth testing in MASH patients
    44%
    Current

    Recent market research we conducted shows that 44% of hepatologists and 27% of gastroenterologists reported they already used PEth testing in their MASH patients.

    Gastroenterologists using PEth testing in MASH patients
    27%
    Current

    Recent market research we conducted shows that 44% of hepatologists and 27% of gastroenterologists reported they already used PEth testing in their MASH patients.

    AUD patients with ALD overlap
    50%
    Current

    It is important to note that approximately 50% of AUD patients also have ALD.

    RESTORE Phase 2 ALD trial enrollment
    120
    Completed

    The trial enrolled approximately 120 patients with ALD and a history of chronic and heavy drinking at baseline.

    Industry KPIs

    3
    MetricValueDetails
    Pipeline read out calendarPERFORMA Phase 3 MASH 52-week data readout
    Regulatory approvals filingsEnd of Phase 2 meeting with FDA
    Clinical trial efficacy safety dataStatistically significant reduction in heavy drinking days

    Risks & headwinds

    3
    Increased R&D expensesQ2 FY26

    $18.7 million in Q2 FY26, up from $17.2 million in Q2 FY25

    Mitigation: Investment into ALD trial and MASH Phase 3 startup costs

    Increased G&A expensesQ2 FY26

    $7.6 million in Q2 FY26, up from $5.7 million in Q2 FY25

    Mitigation: Driven by professional fees and compensation expenses

    AUD Phase 3 trial not yet fundedFuture

    N/A

    Mitigation: Plan to use non-dilutive means (royalty, debt, strategic partnerships) to fund the trial

    What to watch in Q3 FY26

    4

    AUD Phase 3 trial design and timing

    Next quarter / following quarters
    CurrentEnd of Phase 2 meeting with FDA planned; not yet guiding on timing
    TargetSpecifics on Phase 3 trial design, scope, and estimated timeline

    Why it matters

    Determines the path to market for pemvidutide in AUD, a significant potential indication.

    We are moving quickly to gather the full data from the trial, then prepare the data package to request an end of Phase 2 meeting with the FDA to discuss next steps.

    Q&A highlights

    7

    How is Altimmune managing patient enrollment in the competitive MASH trial landscape, particularly regarding site overlap with other ongoing pivotal programs like semaglutide or survodutide?

    Management is confident in PERFORMA's design, site relationships, and reasonable patient targets per site, aiming for the lower end of an 18-24 month enrollment timeline. They leverage experience from CROs and sites, and the AIM-MASH Assist technology helps reduce screen failures.

    Our enrollment is around, for studies in that nature, between 18 to 24 months. We are, because of this, different aspects that are, we heard they are very attractive for the PIs. We are aiming at the lower end of this, and that fits well with what we're hearing right now.

    asked by Thomas Smith · answered by Christophe Arbet-Engels

    3 min read6 chapters

    Detailed Narrative

    01

    PERFORMA Phase 3 MASH Trial Initiation and Design

    Altimmune initiated the global PERFORMA Phase 3 trial for MASH, enrolling patients just three months after securing funding. The trial will span approximately 300 sites, with one-third in the U.S. and two-thirds internationally. Management expressed confidence in efficient enrollment, aiming for the lower end of an 18-24 month timeline, leveraging strong site relationships and the AIM-MASH Assist technology to reduce screen failures and improve consistency in pathology readings. The trial allows GLP-1 use at anti-diabetic doses but excludes resmetirom to protect the primary endpoint.

    02

    RECLAIM Phase 2 AUD Data Highlights Pemvidutide's Potential

    The RECLAIM Phase 2 trial in Alcohol Use Disorder (AUD) reported strongly positive top-line data, meeting its primary endpoint with a statistically significant reduction of 1.45 heavy drinking days per week for pemvidutide 2.4 mg versus placebo. Key secondary endpoints, both recognized by the FDA as registrational, were also met: a 2-level reduction in WHO Risk Drinking Levels (achieved by two-thirds of pemvi patients) and a significant increase in 0 heavy drinking days (achieved by more than twice the number of pemvi patients). The trial also showed a 9.1% body weight reduction and encouraging FIB-4 improvement in patients with elevated baseline levels.

    03

    Pemvidutide's Differentiated Profile in Liver Diseases

    Management emphasized pemvidutide's balanced 1:1 glucagon and GLP-1 agonism as a key differentiator, particularly for its potential direct effects on the liver. This dual mechanism is believed to address the totality of disease in AUD and ALD patients by reducing alcohol cravings while also providing liver benefits. This positions pemvidutide uniquely against other GLP-1 therapies, especially for higher-risk patients who often present with existing liver impairment.

    04

    Significant Unmet Need and Market Opportunity in AUD

    The AUD market represents a considerable untapped opportunity, with approximately 12 million U.S. adults suffering from moderate to severe AUD, a population highly susceptible to liver damage. Despite significant health consequences, only 10% of AUD patients are diagnosed, and only one in four receives drug therapy. Altimmune believes pemvidutide's efficacy and potential liver benefits could disrupt this stagnant market, setting new expectations for drug therapy and increasing diagnosis rates, potentially driven by increased alcohol screening and PEth testing among liver specialists.

    05

    RESTORE Phase 2 ALD Trial Progress and Protocol Amendment

    Enrollment for the RESTORE Phase 2 trial in Alcoholic Liver Disease (ALD) has been completed, with top-line data expected in the second half of 2027. The trial protocol was amended to allow for a hierarchical assessment of liver stiffness measurements (LSM) at week 48, followed by week 24. This change aims to more fully demonstrate pemvidutide's long-term liver benefits, aligning with the company's strategy to focus on higher-risk patients and differentiate the drug based on its liver impact.

    06

    Financial Strength and Non-Dilutive Funding Strategy

    Altimmune reported a strengthened financial position with $519 million in cash as of June 30, 2026, following a $225 million follow-on offering in April. This provides an operating cash runway through the MASH Phase 3 52-week data readout in 2029. For the potential AUD Phase 3 trial, the company's preference is to secure non-dilutive funding, exploring options such as royalties, debt, or strategic partnerships, rather than relying on further equity dilution.

    AI-generated summary of the company’s earnings call. Not investment advice.